TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7493311
Drug: L-IFN 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-IFN 3 MU thrice weekly (group C)
Study: 19756431
Drug: Peri-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peri-operative chemotherapy
Study: 2148877
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no peri-operative chemotherapy)
Study: 28961845
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg apatorsen
Study: 28961845
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg apatorsen
Study: 28961845
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg apatorsen (poor prognostic features)
Study: 28961845
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg apatorsen (lower sHsp27 levels)
Study: 28961845
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg apatorsen (lower sHsp27 levels)
Study: 25742559
Drug: Acoustic wave
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic wave therapy (AWT)
Study: 24444704
Drug: Standard conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conservative treatment (control)
Study: 19829175
Drug: Lifestyle changes,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle changes, pharmacotherapy, and psychologic interventions
Study: 11323363
Drug: Small Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small Ketamine (0.25 mg/kg)
Study: 11323363
Drug: Large Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large Ketamine (1.0 mg/kg)
Study: 9217714
Drug: Picotamide, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide, 600 mg twice daily
Study: 3118579
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus glibenclamide
Study: 2256787
Drug: Cefotaxime continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime continued treatment
Study: 2256787
Drug: Ampicillin replacement
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin replacement treatment
Study: 2256787
Drug: Phenobarbitone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone administration
Study: 2256787
Drug: IV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV treatment cessation by the 10th day
Study: 2256787
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with IIIrd generation cephalosporin
Study: 2256787
Drug: Substitution by
Normalized name: hydroxypropyl corn starch (5% substitution by weight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitution by ampicillin or amoxicillin
Study: 1137256
Drug: Computer-assisted digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer-assisted digoxin therapy
Study: 1137256
Drug: Physician-regulated digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician-regulated digoxin therapy
Study: 27531181
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly 400 mg
Study: 24925984
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole (10-30 mg/day)
Study: 24925984
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly 50 mg
Study: 22552758
Drug: Saffron (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (15 mg twice per day)
Study: 15523183
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (RH)
Study: 12490271
Drug: Angiopeptin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiopeptin 1.5 mg
Study: 9620513
Drug: Ketamine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.4 mg/mL
Study: 7542134
Drug: Finasteride (Proscar)
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride (Proscar) therapy for BPH
Study: 19736899
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil (5 microg) plus intrathecal morphine (150 microg)
Study: 19736899
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil (5 microg) plus single administration of 10 mg subcutaneous morphine
Study: 17163810
Drug: Sitaxsentan with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan with concomitant warfarin
Study: 52854
Drug: Oxprenolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (60 mg per day) and Quinidine (0.60 g per day)
Study: 52854
Drug: Quinidine (0.80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (0.80 g per day)
Study: 30676622
Drug: Avelumab, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study
Study: 26729394
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care and early electrical stimulation (ES) to the wrist flexors and extensors for 30 min twice a day, 5 days a week for 3 months
Study: 22151064
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg · kg(‐1) GHB
Study: 22151064
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg · kg(‐1) GHB
Study: 22151064
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg · kg(‐1) GHB
Study: 20619853
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (10 or 20 mg/day depending on age) for 10 days
Study: 15726891
Drug: High-AGE (AGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-AGE (AGE 2.4 ml/day)
Study: 15726891
Drug: Low-AGE (AGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-AGE (AGE 0.16 ml/day)
Study: 31174215
Drug: Fe (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe (60 mg)
Study: 27798075
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of mephedrone administered orally
Study: 16922941
Drug: Pulsed Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Dye Laser (PDL) therapy following 30% Salicylic Acid (SA) application twice a day for 5 days
Study: 16922941
Drug: Pulsed Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Dye Laser (PDL) therapy alone
Study: 12712081
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment for three cycles followed by placebo for one cycle
Study: 12712081
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for three cycles followed by placebo for one cycle
Study: 11085959
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies to cardiolipin
Study: 8500859
Drug: Captopril monotherapy
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril monotherapy or combined with hydrochlorothiazide
Study: 8500859
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (metoprolol, hydrochlorothiazide, or both)
Study: 8500859
Drug: Captopril or
Normalized name: captopril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril or conventional therapy
Study: 29396092
Drug: Romiplostim (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (750 μg subcutaneously once per week for 58 weeks)
Study: 11920549
Drug: Individualized uncertainty
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized uncertainty management intervention delivered by telephone (weekly phone calls for 8 weeks)
Study: 2113376
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course (SC) of systemic antibiotics
Study: 2113376
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course (LC) of systemic antibiotics
Study: 391657
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg on entering the study followed by 400 mg six hourly)
Study: 31614295
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training for 8 weeks, 7 days per week, twice daily
Study: 19398166
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine replacement therapy
Study: 16926171
Drug: Combination program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination program
Study: 14960294
Drug: Estradiol (.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (.1 mg/day)
Study: 11502805
Drug: Dexamethasone and
Normalized name: dexamethasone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone and prednisone treatment
Study: 7953934
Drug: Comprehensive oral
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive oral health care programme
Study: 2885080
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin and bleomycin) followed by standard therapy (surgery and postoperative radiotherapy)
Study: 2885080
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and standard therapy followed by maintenance chemotherapy (six cycles of monthly cisplatin)
Study: 10812285
Drug: THC (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (15 mg)
Study: 27514628
Drug: Routine Medical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Medical Therapy (RMT)
Study: 25394549
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage (15 minutes, 2 times daily for 5 days)
Study: 11061773
Drug: Epinephrine inhalation
Normalized name: EPINEPHrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine inhalation
Study: 6135439
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg (i.v.) doxazosin
Study: 6135439
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg (oral) doxazosin
Study: 31337171
Drug: AAJ injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAJ injection with 1.0 mL of a mixture of 0.5 mL of bupivacaine 0.5% and 0.5 mL of 20 mg of triamcinolone, plus oral placebo tablets (2 tablets every 8 hours for one week)
Study: 31337171
Drug: Systemic steroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroids, oral prednisolone tablets (5 mg, 2 tablets every 8 hours for one week), plus AAJ injection with 1.0 mL of a mixture of 0.5 mL of bupivacaine 0.5% and 0.5 mL of normal saline solution
Study: 29386173
Drug: Web-based tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based tailored cognitive behavioral therapy (CancerCope)
Study: 27028912
Drug: Oral 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17β‐estradiol (1 mg per day, plus progesterone [45 mg] vaginal gel administered sequentially for women with a uterus)
Study: 27028912
Drug: Placebo (plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (plus sequential placebo vaginal gel for women with a uterus)
Study: 27028912
Drug: Oral 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17β‐estradiol and Placebo
Study: 22824593
Drug: Grid laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grid laser treatment alone
Study: 22824593
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravitreal injection of ranibizumab (0.5 mg / 0.05 ml) followed by grid laser treatment on 7th day
Study: 22824593
Drug: Three loading
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three loading doses of intravitreal ranibizumab at monthly intervals + standard laser treatment 7 days after the 1st injection
Study: 17229788
Drug: Consistent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent use of a supervised safer injection facility (SIF)
Study: 17229788
Drug: Inconsistent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inconsistent use of a supervised safer injection facility (SIF)
Study: 9843009
Drug: 0.05% retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% retinaldehyde cream
Study: 7978141
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia regimen using morphine 1 mg.ml‐1 solution
Study: 7978141
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia regimen using morphine 1 mg.ml‐1 with metoclopramide 0.5 mg.ml‐1 solution
Study: 2609898
Drug: Dithranol-Biogram formulation
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithranol-Biogram formulation (1% dithranol applied for 20 min after UV-B treatment)
Study: 2609898
Drug: Conventional ex-tempore
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ex-tempore formulation (1% dithranol applied for 20 min after UV-B treatment)
Study: 30477834
Drug: Lipoic Acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoic Acid (LA) 1200 mg daily for 2 years
Study: 26132079
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E)
Study: 21910067
Drug: Xiongshao Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiongshao Capsule (XS)
Study: 12715913
Drug: Tongue and
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue and oral mucosa cleaning (oral care) after lunch every day or every other day for two consecutive weeks
Study: 11061760
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment (Curosurf, Survanta, Alveofact, Exosurf)
Study: 20089269
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ciprofloxacin twice a day for 4 weeks
Study: 18448709
Drug: Aggressive chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive chemotherapy for a 65-year-old patient
Study: 18448709
Drug: Aggressive chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive chemotherapy for a 25-year-old patient (physician role)
Study: 18448709
Drug: Aggressive chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive chemotherapy for a 25-year-old patient (abstract other role)
Study: 18448709
Drug: Aggressive chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive chemotherapy for a 25-year-old patient (self role)
Study: 16125527
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone plus testosterone (GH plus T) administration
Study: 16125527
Drug: Sex steroid
Normalized name: Sex steroid binding globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex steroid administration (hormone replacement therapy in women, testosterone enanthate in men)
Study: 11870507
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment with radioimmunotherapy in glioblastoma patients
Study: 11870507
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment with radioimmunotherapy in grade III glioma patients
Study: 10701474
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 75-225 mg/day (n = 100)
Study: 10701474
Drug: Fluoxetine 20-60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20-60 mg/day (n = 103)
Study: 2110703
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b polysaccharide‐protein conjugate vaccine (PRP‐D) mixed with meningococcal and/or pneumococcal capsular polysaccharide vaccines
Study: 2110703
Drug: Halved vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halved vaccine dose
Study: 2110703
Drug: Multiple vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple vaccine antigens
Study: 760017
Drug: Cephradine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine (1 g preoperatively followed by 500 mg IV q. 6 hours for 4 doses)
Study: 760017
Drug: Cephradine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine (2 g IV given approximately 1 hour before surgery)
Study: 26514220
Drug: Subcutaneous local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous local analgesic infusion (ScLAI) with bupivacaine
Study: 18488437
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with tiotropium
Study: 17489939
Drug: Aminophylline infusion
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline infusion
Study: 25468986
Drug: Subjects requesting
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects requesting antibiotics (overall comparison)
Study: 20158291
Drug: Triazolam (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125 mg/70 kg, oral)
Study: 20158291
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 mg/70 kg, oral)
Study: 20158291
Drug: Scopolamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.25 mg/70 kg, subcutaneous)
Study: 20158291
Drug: Scopolamine (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.50 mg/70 kg, subcutaneous)
Study: 12422622
Drug: Aronia in
Normalized name: Aronia melanocarpa fruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aronia in combination with apple pectin (15 g of apple pectin and 20 ml of Aronia concentrate twice daily)
Study: 1677212
Drug: L-threonine, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threonine, dosage and duration not specified
Study: 7037662
Drug: Pivampicillin (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin (350 mg, three times daily for 15 days)
Study: 7037662
Drug: Ampicillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (250 mg, three times daily for 15 days)
Study: 30845690
Drug: Functional olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional olive oil (FOO, 487 ppm of phenolic compounds and enriched with 389 ppm of triterpenes)
Study: 27841790
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray (saline spray)
Study: 27841790
Drug: Lipid spray
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid spray (phosphatidylcholine; Tears again)
Study: 27841790
Drug: Symptomatic wearers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic wearers with spray treatment
Study: 26825840
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with or without radiation therapy (RT) (intravaginal or pelvic)
Study: 26825840
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (intravaginal RT or pelvic RT) alone
Study: 8092508
Drug: Eltanolone 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanolone 0.6 mg/kg
Study: 3046851
Drug: Cefodizime (CDZ)
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime (CDZ) - 2 g daily dose i.v. for 6 days to patients and for 4 days to healthy subjects.
Study: 30304237
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (50 mg/kg daily)
Study: 28734717
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice a day for 7 days)
Study: 28734717
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (standard of care)
Study: 21990307
Drug: 2.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g/d ginger
Study: 12956319
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (0.4 g x d(‐1))
Study: 11831450
Drug: Inhaled formoterol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol, twice daily for 4 weeks
Study: 31467052
Drug: New service
Approvals — FDA: no, EMA: no, PMDA: no
Description: New service delivery model including case management, counselling, AAC training, and AAC therapy.
Study: 11309556
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily for 7 days
Study: 9295896
Drug: Fraxiparine 3075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraxiparine 3075 IU AXa (fixed dosage)
Study: 9295896
Drug: Fraxiparine 4100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraxiparine 4100 or 6150 IU AXa (dosage adjusted for body weight)
Study: 8314476
Drug: Interferon alfa‐2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b, 3 million units subcutaneously, thrice weekly for 12 months